Clinical Trial Update: Blood for Immune Response to Provenge® in HRPC

View source ↗

Summary

Clinical trial evaluating blood-based immune response to Provenge in hormone-refractory prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PROVENGE (sipuleucel-T)

Snippet

Sponsor: Mary Crowley Medical Research Center | Conditions: Prostate Cancer | Status: WITHDRAWN